Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Future Fund LLC

Future Fund LLC reduced its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 69.4% in the third quarter, according to its most recent filing with the SEC. The fund owned 11,096 shares of the biopharmaceutical company's stock after selling 25,199 shares during the period. Halozyme Therapeutics comprises 1.9% of Future Fund LLC's portfolio, making the stock its 26th biggest position. Future Fund LLC's holdings in Halozyme Therapeutics were worth $634,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of HALO. GAMMA Investing LLC grew its stake in Halozyme Therapeutics by 96.6% in the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 254 shares in the last quarter. International Assets Investment Management LLC purchased a new position in shares of Halozyme Therapeutics during the second quarter valued at $33,000. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Halozyme Therapeutics in the second quarter valued at about $49,000. Toth Financial Advisory Corp purchased a new stake in Halozyme Therapeutics in the third quarter worth about $57,000. Finally, FSC Wealth Advisors LLC bought a new position in Halozyme Therapeutics during the 3rd quarter worth about $65,000. Hedge funds and other institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Stock Performance

HALO stock traded down $1.08 during trading on Wednesday, reaching $58.53. The company had a trading volume of 364,809 shares, compared to its average volume of 1,285,674. The company has a market cap of $7.45 billion, a price-to-earnings ratio of 19.48, a price-to-earnings-growth ratio of 0.55 and a beta of 1.29. Halozyme Therapeutics, Inc. has a twelve month low of $33.15 and a twelve month high of $65.53. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. The firm has a 50-day simple moving average of $56.53 and a 200-day simple moving average of $53.18.

Insider Buying and Selling

In other news, CEO Helen Torley sold 10,000 shares of the stock in a transaction dated Wednesday, October 9th. The stock was sold at an average price of $52.58, for a total value of $525,800.00. Following the transaction, the chief executive officer now directly owns 676,744 shares of the company's stock, valued at approximately $35,583,199.52. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 70,000 shares of company stock worth $4,042,500 in the last 90 days. Insiders own 2.40% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on HALO. Piper Sandler boosted their price target on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the company a "neutral" rating in a report on Monday, November 4th. TD Cowen lifted their price target on Halozyme Therapeutics from $59.00 to $65.00 and gave the company a "buy" rating in a report on Wednesday, August 7th. Wells Fargo & Company cut Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and upped their price objective for the stock from $58.00 to $62.00 in a research note on Monday, October 7th. JMP Securities lifted their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a "market outperform" rating in a research note on Friday, November 1st. Finally, Morgan Stanley increased their price target on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the company an "overweight" rating in a research report on Wednesday, August 7th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $61.11.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.